



The Change Complete Blood Count And Other Inflammatory Markers Before And After Sinopharm Coronavirus Vaccine

¹HUSSEIN KAREEM ELAIBI, ²FARAH FAKHIR MUTLAG

¹hospital al-hussein medical, ²teacher

¹kerbala unversity,

²kerbala university

ABSTRACT

Background: Since 2019 (COVID-19) was designated a pandemic, it became apparent that vaccination was the best way of dealing with it. A few vaccinations of COVID-19 were produced and approved in less than a year. Many questions about the vaccinations' efficacy and safety arose due to this unprecedented vaccine development effort. This study aimed to Eliminate health illiteracy and evaluate the side effects and impressions of sinopharm vaccination in Iraq.

Methods: A study was conducted on volunteers who received vaccines for the inactivated coronavirus (sinopharm), and their number was 40 people, 20 women and 20 men, who were tested for inflammatory factors before the vaccine, and after seven days, the tests were repeated after which the data were statistically analyzed, and the test (t-Test) was used, including This is a questionnaire Predicting the seriousness of side effects.

Results: A total of 40 participants participated in the test before and after receiving the Sinopharm vaccination. The most prevalent and non-life-threatening side effects of post-vaccination were (e.g. chills, dizziness, fever, headache, joint pain, and myalgia). Only 2.5% of individuals had severe adverse effects, whereas 97.5% reported moderate and mild side effects. Although the presence and severity of side effects of these vaccinations are numerous, statistical studies have found that they can offer equal protection from COVID-19. There are no severe side effects. The results of white blood cells and other inflammatory factors showed that they completely disappear after seven days, and there is no fear because the side effects last from several hours to 24 hours after the vaccine. This is what distinguishes inactivated vaccines and their importance

Conclusions: The present investigation demonstrated that they are safe with COVID-19 vaccinations and that being vaccinated makes individuals feel safer. The majority of adverse effects post-vaccination are low to moderate, indicating a strengthening of the body's defence immunological system. When examining all cells, white blood cells, platelets, sedimentation factors, and CRP, a protein found in the blood at levels that rise in response to the inflammatory condition. All of them have no statistical relationship after seven days of vaccination. This increases our confidence in inactivated sinopharm vaccines. The emergence of the single case did not adhere to preventive measures immediately after the vaccine.

Keywords: sinopharm vaccine, complete blood count, C-reactive protein, sedimentation

INTRODUCTION

Covid 19 (New Coronavirus Infection) is a pandemic virus that spreads swiftly throughout the world, including our country. Pneumonia causes the unclear cause first reported in Wuhan, Hubei Province, China, at the end of 2019. [1], [2]. Pneumonia swiftly spread throughout China and beyond. It's still in the early stages. COVID-19 has developed into a worldwide epidemic that is wreaking havoc on the world's health systems.. [3][4]. Several studies have found that health care employees have much higher rates of depression, anxiety, sleeplessness, and emotional discomfort than the general population. [5]. Despite the viruses global spread, many people have survived infection and are nonetheless susceptible to SARS-CoV-2. Vaccination can improve population immunity, avoid severe disease, and alleviate the current health crisis. It appears to be the only way to stop the virus from spreading. Rapid international efforts to develop and test SARS-CoV-2 vaccines have resulted in an extraordinary number of candidate vaccines beginning clinical trials in 2020.[6]. A few licensed COVID-19 vaccinations and attempts are being undertaken to develop safe and effective vaccines for COVID-19 prevention. Around 64 vaccine candidates are being evaluated in clinical trials, according to the WHO draft landscape of COVID-19 candidate vaccines. Vector vaccines (AstraZeneca, CanSino, and Janssen), mRNA-based vaccines (Moderna and Pfizer), inactivated vaccines (SinoVac/Sinopharm, and Bharat Biotech), and adjuvanted recombinant protein nanoparticles (SinoVac/Sinopharm, and Bharat Biotech) are among the phase 3 vaccine possibilities (Novavax) [7]. Pfizer, AstraZeneca, Johnson & Johnson, Moderna, and Sinopharm have all had vaccines approved by the World Health Organization. Although this revolutionary vaccine technique is safe, the vaccines' side effects have yet to be thoroughly described. Understanding the side effects of the licensed COVID-19 vaccinations is critical given the vaccine's relevance in combating this public health catastrophe. The Sinopharma inactivated vaccine will be investigated. The benefit of using Wuhan Institute inactivated vaccination is that the pathogen is removed and there is no danger of recurrence due to the use of an inactive virus. These vaccinations may be kept at room temperature in the refrigerator, which is a significant advantage..[8]. Various vaccines have been developed around the world to help manage the covid-19 outbreak. Differences in how vaccines were produced resulted in a slew of difficulties with efficacy and adverse effects. This answers some of the questions about vaccines, their manufacturing sources, doses, and storage conditions. In the case of COVID-19 patients, health staff are the last line of defence. The primary purpose of the present immunization is to prevent and minimize the spread of COVID-19. The availability of various vaccines is expected to provide strategic responses to the pandemic crisis that has afflicted diverse places worldwide.[9]. The vaccine campaign is designed to establish herd immunity of at least 70% in a population, allowing it to recover from the pandemic and resume regular life quickly. The presence of virus mutations is one of the elements that can alter vaccine effectiveness. Thus more research into the effectiveness of viral genetic mutations is still needed.[10].

Inactivated vaccines

Wuhan Biopharmaceutical Institute/Sinopharm, Beijing Beijing Institute of Biopharmaceuticals, and Sinovac Institutes developed the Inactivated platform. All of them are through phase 3 clinical studies. Inactivated candidate vaccines are used by Wuhan Institute, while Sinovac Institutes use inactivated aluminium adjuvant. The complete virus is the target antigen in these three institutions' vaccines, and the only Wuhan Institute's target antigen is several doses. The Wuhan Institute vaccination induces a higher humoral immune response. Furthermore, the Sinovac Institute's immune response is predominantly humoral, which will enhance the presence of aluminium adjuvant. The benefit of [11], [12].

Vaccines manufacturing major government companies in china

In China, the government owns the majority of healthcare facilities. CNBG enterprises, China's top vaccine makers, are the country's primary government establishments on vaccination-related healthcare issues.[13]. Aside from other assets, CNBG has six institutes of biological products; the six institutes are also involved in manufacturing, distributing, and marketing vaccines through their production firms and institutions located around China. There are a few other privately-held biotech companies that manufacture vaccines in the United States. CNBG firms supply more than half of all vaccinations consumed in mainland China. CNBG is a biotech company focused on research and development, manufacturing, marketing, and distributing vaccines and blood products.[14][15].

Sinopharm Vaccine

Sinopharm, on the other hand, employs a long-established strategy that has proven successful in other vaccines, such as polio and flu shots. Their coronavirus vaccines use an inactivated full virus to induce immunity in the body and be stored at typical refrigerator temperatures of 2 to 8 degrees Celsius (36 F to 46 F). Other Chinese vaccines in development can be stored at the same temperatures. China vaccine is 86 per cent effective, according to the UAE. Coronavirus. 1 million Chinese people have given the Sinopharm vaccination as part of an emergency usage program.[16], [17].

Materials and Methods

Patients

forty people of the vaccine recipients (20 females and 20 males, mean age = 36.5, range 18-62 yr). They do not suffer from any disease (They all received a sinopharm vaccine). Blood was drawn several hours before vaccination and seven days after vaccination. They did not receive any medication within seven days.

Materials

Equipment has been used MONARCH-300, DIRUI CS-T180 and Sysmex XP 300 Checked erythrocyte sedimentation rate (ESR), C-reactive protein, White blood cells, Neutrophil, Lymphocyte


Exclusion criteria

- Type 1&2 diabetes
- Cancer
- Chronic liver disease
- Pregnancy
- Chronic renal disease

Every one of the participants was in good health., and we were careful not to use the drug during the period after the vaccination; and they were suffering from simple symptoms (chills, headache, fever, dizziness, myalgia, and headache) in the vaccine and it lasted less than 24 hours

RESULT

A total of 40 patients, 20 women and twenty men, Before the vaccination, blood was obtained, and blood was drawn again seven days later. The most prevalent and non-life-threatening side effects of post-vaccination were (e.g., chills, headache, fever, dizziness, myalgia, and headache).



Tablo.1 Distribution of volunteers before and seven days after vaccination

	Before vaccine Mean±SD	After vaccine Mean±SD	P-Value
ESR	8.56±7.25	11.56±10.63	0.14**
C-rp	2.67±6.71	2.06±4.48	0.64**
RBC	4.76±0.63	4.92±0.62	0.25**
HGB	13.1±1.53	13.6±1.44	0.11**
WBC	7.89±2.21	8.46±1.39	0.18**
NEU	48.04±7.83	46.05±9.58	0.32**
LYM	40.65±7.57	43.57±8.84	0.12**
PLT	222.4±85.19	244.8±54.9	0.17**
GLU	84.58±13.08	88.97±20.09	0.25**

* p< 0.05 statically significant

**p > 0.05 not statically significant

Tablo.2 The side effect of sinopharm vaccine

The side effects	The ratio
chills	75%
dizziness	25%
fever	47.5
headache	10%
joint pain	15%
myalgia	80%

Discussion

According to the present study, the authorized sinopharm vaccine is safe, and getting vaccinated makes individuals feel safer. The majority of post-vaccination side effects are mild to moderate, indicating that the body's immune system improves. Chills, disorientation, fever, headache, joint discomfort, and myalgia were among the most common and non-life-threatening post-vaccination side effects.) [18]. On the other hand, about 45 % per cent of those who received the initial dosage received the SP vaccination, which has few side effects. The majority of subjects who got the SP vaccination reported no side effects after either of two doses, confirming the vaccine's low immunogenic potential. The safety profile of inactivated vaccines is excellent. They do, however, require a booster plan to develop immunological memory. [19]. The erythrocyte sedimentation rate (ESR), C-reactive protein, White blood cells, Neutrophil, and Lymphocyte, were factors and markers that lead to inflammation in the body. There is no statistical difference between the two groups before and after vaccination. Previous research has shown that the rate of inflammation in the body rises for the first 24 hours. It then returns to normal, consistent with our findings, showing no statistical relationships that indicated the presence of infections seven days after receiving the infection vaccine. [20]. In another trial, most of the effects peaked 24 hours after injection and returned to baseline within 1 to 3 days. [21].

Conclusion

Reactogenicity symptoms are a result of the immunological reaction that happens as a result of vaccination. On the other hand, symptoms are impacted by various factors, many of which can be mitigated by educating vaccine users, providing an acceptable vaccination setting, and utilizing appropriate injection procedures. In these endeavours, healthcare professionals play a critical role.

REFERENCES

- [1] C. Huang *et al.*, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China," *Lancet*, vol. 395, no. 10223, pp. 497–506, 2020.
- [2] N. Chen *et al.*, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study," *Lancet*, vol. 395, no. 10223, pp. 507–513, 2020.
- [3] C. J. Wang and S. Worswick, "Cutaneous manifestations of COVID-19," *Dermatol. Online J.*, vol. 27, no. 1, 2021.
- [4] A. Ali *et al.*, "Covid-19 and Acute Coronary Syndrome (ACS): A Review of its Pathophysiology, Prevalence and Management during the Pandemic," *Arch. Intern. Med. Res.*, vol. 4, no. 2, pp. 66–76, 2021.
- [5] A. Afzal, M. Kamal, N. Diyanti, R. D. Proano, and A. Jaan, "Implementation of Mandatory Counseling Sessions and Availability of Support Centers for Mental Well Being of Health Care Workers during the COVID-19 Pandemic," *Arch. Intern. Med. Res.*, vol. 4, no. 1, pp. 43–45, 2021.
- [6] M. Voysey *et al.*, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK," *Lancet*, vol. 397, no. 10269, pp. 99–111, 2021.
- [7] D. Y. Logunov *et al.*, "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia," *Lancet*, vol. 397, no. 10275, pp. 671–681, 2021.
- [8] C. Baraniuk, "What do we know about China's covid-19 vaccines?," *bmj*, vol. 373, 2021.
- [9] F. Ortega and M. Orsini, "Governing COVID-19 without government in Brazil: Ignorance, neoliberal authoritarianism, and the collapse of public health leadership," *Glob. Public Health*, vol. 15, no. 9, pp. 1257–1277, 2020.
- [10] V. J. Clemente-Suárez *et al.*, "Dynamics of population immunity due to the herd effect in the COVID-19 pandemic," *Vaccines*, vol. 8, no. 2, p. 236, 2020.
- [11] S. Xia *et al.*, "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity

- outcomes: interim analysis of 2 randomized clinical trials," *Jama*, vol. 324, no. 10, pp. 951–960, 2020.
- [12] H. Wang *et al.*, "Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2," *Cell*, vol. 182, no. 3, pp. 713–721, 2020.
- [13] W. H. Organization, *WHO guidelines for indoor air quality: household fuel combustion*. World Health Organization, 2014.
- [14] Y. Wen *et al.*, "Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study," *BMC Infect. Dis.*, vol. 18, no. 1, pp. 1–12, 2018.
- [15] J. Luyten and P. Beutels, "The social value of vaccination programs: beyond cost-effectiveness," *Health Aff.*, vol. 35, no. 2, pp. 212–218, 2016.
- [16] K. N. Uddin, "Corona vaccine," *BIRDEM Med. J.*, vol. 11, no. 1, pp. 1–5, 2021.
- [17] P. K. Ghosh, "Human vaccines industry in China, 2019: Part—I," *MGM J. Med. Sci.*, vol. 7, no. 1, p. 35, 2020.
- [18] E. J. Anderson *et al.*, "Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults," *N. Engl. J. Med.*, vol. 383, no. 25, pp. 2427–2438, 2020.
- [19] J. Rodriguez Coira and M. Sokolowska, "SARS-CoV-2 candidate vaccines-composition, mechanisms of action and stages of clinical development," *Allergy*, 2020.
- [20] C. Hervé, B. Laupèze, G. Del Giudice, A. M. Didierlaurent, and F. T. Da Silva, "The how's and what's of vaccine reactogenicity," *npj Vaccines*, vol. 4, no. 1, pp. 1–11, 2019.
- [21] W. Burny *et al.*, "Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans," *Vaccine*, vol. 37, no. 14, pp. 2004–2015, 2019.

